Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform
- Curve’s innovative mammalian cell drug discovery platform to enable identification and optimisation of novel small molecule drug candidates against MSD targets
- Potentially game-changing platform enables direct discovery of functionally active molecules against difficult to drug targets expressed in their native intracellular environment
Southampton, UK, 16th February 2022: Curve Therapeutics (Curve), a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces a global research collaboration with MSD, the trade name of Merck & Co., Inc., Kenilworth, NJ USA, to discover and validate modulators of up to five therapeutic targets using its Microcycle® technology, initially for oncology and neurology indications.
